Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q3 2016 call → NOWe need answer YES/NO. Need determine if management conveys company today running on different basis than reported results/reputation built on, with both halves: change already real, and record/perception lag. Transcript: Fate Therapeutics. They discuss progress: ProTmune clinical trial, FATE-NK100 IND filed, ToleraCyte, iPSC platform off-the-shelf. Are they saying company has crossed into different kind of business? Need see if management describes change of basis already real and results/outside picture lag. Scott: "Fate Therapeutics is developing groundbreaking cellular immunotherapies and is pioneering the use of engineered pluripotent cell lines to develop off-the-shelf cell therapy products, a revolutionary approach that moves beyond reliance on patient source cells..." This is vision? They have initiated clinical translation of first off-the-shelf product candidate? "We have now initiated clinical translation of our first off-the-shelf product candidate for a more induced pluripotent cell platform and engineered high affinity CD 16 natural killer cell." But is that already real? They plan to submit briefing package to FDA. Not yet clinical. They formed partnership with MSK. They have IP. But is this a change of basis? Company historically? Need infer from transcript. They are developing cellular immunotherapics. They have ProTmune (ex vivo modulated graft) and NK cells. The "different basis" might be moving from patient-specific to off-the-shelf engineered iPSC. But management describes as "pioneering" and "opportunity to be first" - future. Not yet results. Also reported results are from Juno collaboration revenue. They don't say results lag. Question asks: "does management itself describe the company as having crossed, recently and substantially, into being a different kind of business than it was, while making clear that this change is not yet what the reported numbers or the outside picture of the company reflect?" Need answer YES only if both halves. Management does not explicitly say "company today is running on different basis than reported results/reputation." They talk about progress and intensified clinical commitment. They don't say reported numbers lag. They don't contrast old vs new business. They mention "revolutionary approach" but as future.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...